Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis.

IF 1.2 Q4 ENDOCRINOLOGY & METABOLISM

Diabetology International Pub Date : 2024-10-15 eCollection Date: 2025-01-01 DOI:10.1007/s13340-024-00765-y

Carlos U Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, Leonardo M Porchia, Ricardo Pérez-Fuentes, M Elba Gonzalez-Mejia

{"title":"Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis.","authors":"Carlos U Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, Leonardo M Porchia, Ricardo Pérez-Fuentes, M Elba Gonzalez-Mejia","doi":"10.1007/s13340-024-00765-y","DOIUrl":null,"url":null,"abstract":"Aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce visceral (VAT) and subcutaneous (SAT) adipose tissue. Although many systematic reviews have examined SGLT2i's effect on VAT and SAT, a focus analysis of dapagliflozin, one of the more commonly prescribe SGLT2i, has yet to been done. This study aims to determine the effect of dapagliflozin on reducing VAT and SAT in patients with chronic disease.Methods: SCOPUS, PubMed, EBSCO, and LILACS databases were searched until December 26, 2023. Heterogeneity was determined using Cochran's Q test and quantified using the inconsistency index. The random-effects model was used to calculate the pooled standardize difference in means (SDM) and 95% confidence intervals (95% CI). Duval and Tweedie trim and fill (DT), Egger's test, and Beggs-Muzamar's test were used to assess publication bias. PROSPERO: CRD42023426208.Results: Twelve reports were included (treated = 299 and controls = 301). Overall, dapagliflozin treatment reduced VAT (SDM = - 0.406, 95% CI: - 0.526 to - 0.286, p < 0.001) and SAT (SDM = - 0.439, 95% CI: - 0.601 to - 0.278, p < 0.001). These results were stable as determined with a sensitivity analysis; however, there was potential publication bias. Two and three imputed studies were determined by the DT method for VAT and SAT, respectively. When stratified by pathology (obesity, T2D, and T2D/NAFLD), dapagliflozin treatment decreased VAT and SAT for all conditions. However, for specifically SAT, only when compared between T2D and T2D/NAFLD, T2D/NAFLD was associated with a twofold decrease (p = 0.003).Conclusion: Treatment with dapagliflozin resulted in a significant reduction in VAT and SAT in patients with obesity, T2D, or T2D/NAFLD.Supplementary information: The online version contains supplementary material available at 10.1007/s13340-024-00765-y.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"65-77"},"PeriodicalIF":1.2000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769893/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-024-00765-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce visceral (VAT) and subcutaneous (SAT) adipose tissue. Although many systematic reviews have examined SGLT2i's effect on VAT and SAT, a focus analysis of dapagliflozin, one of the more commonly prescribe SGLT2i, has yet to been done. This study aims to determine the effect of dapagliflozin on reducing VAT and SAT in patients with chronic disease.

Methods: SCOPUS, PubMed, EBSCO, and LILACS databases were searched until December 26, 2023. Heterogeneity was determined using Cochran's Q test and quantified using the inconsistency index. The random-effects model was used to calculate the pooled standardize difference in means (SDM) and 95% confidence intervals (95% CI). Duval and Tweedie trim and fill (DT), Egger's test, and Beggs-Muzamar's test were used to assess publication bias. PROSPERO: CRD42023426208.

Results: Twelve reports were included (treated = 299 and controls = 301). Overall, dapagliflozin treatment reduced VAT (SDM = - 0.406, 95% CI: - 0.526 to - 0.286, p < 0.001) and SAT (SDM = - 0.439, 95% CI: - 0.601 to - 0.278, p < 0.001). These results were stable as determined with a sensitivity analysis; however, there was potential publication bias. Two and three imputed studies were determined by the DT method for VAT and SAT, respectively. When stratified by pathology (obesity, T2D, and T2D/NAFLD), dapagliflozin treatment decreased VAT and SAT for all conditions. However, for specifically SAT, only when compared between T2D and T2D/NAFLD, T2D/NAFLD was associated with a twofold decrease (p = 0.003).

Conclusion: Treatment with dapagliflozin resulted in a significant reduction in VAT and SAT in patients with obesity, T2D, or T2D/NAFLD.

Supplementary information: The online version contains supplementary material available at 10.1007/s13340-024-00765-y.

查看原文本刊更多论文

达格列净治疗减少内脏和皮下脂肪组织：一项系统回顾和荟萃分析。

目的：钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）已被证明可以减少内脏（VAT）和皮下（SAT）脂肪组织。尽管许多系统综述已经研究了SGLT2i对VAT和SAT的影响，但对SGLT2i更常用的处方之一达格列净的重点分析尚未完成。本研究旨在确定达格列净对降低慢性疾病患者VAT和SAT的作用。方法：检索SCOPUS、PubMed、EBSCO、LILACS数据库至2023年12月26日。异质性采用科克伦Q检验确定，不一致性指数量化。随机效应模型用于计算汇总标准化均数差（SDM）和95%置信区间（95% CI）。采用Duval和Tweedie修剪和填充（DT）、Egger检验和Beggs-Muzamar检验评估发表偏倚。普洛斯彼罗:CRD42023426208。结果：纳入12份报告（治疗组299例，对照组301例）。总体而言，达格列净治疗降低了VAT （SDM = - 0.406, 95% CI: - 0.526至- 0.286,p p p = 0.003）。结论：达格列净治疗可显著降低肥胖、T2D或T2D/NAFLD患者的VAT和SAT。补充信息：在线版本包含补充资料，提供地址为10.1007/s13340-024-00765-y。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetology International ENDOCRINOLOGY & METABOLISM-

CiteScore

3.90

自引率

4.50%

发文量

期刊介绍： Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.